Venaxis, Inc. announced that it has begun enrolling patients into its pivotal clinical study in the United States. Based on current enrollment expectations, the company anticipates completing the study in six to eight months and filing with the FDA for regulatory clearance of APPY1 in the fourth quarter 2013.
Market Closed -
Other stock markets
|
After market 19:50:38 | |||
12.7 USD | +10.63% |
|
12.66 | -0.35% |
07:00am | Investors ride the 'Trump trade' as expectations grow for a second term | RE |
07-16 | Top Cryptocurrencies Rise; Bitcoin Advances to $65,000 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.91% | 3.67B | |
+13.75% | 7.29B | |
+79.42% | 4.6B | |
-24.11% | 2.8B | |
+165.83% | 2.13B | |
+64.16% | 2.1B | |
+56.90% | 1.89B | |
+13.39% | 1.54B | |
+5.45% | 1.21B | |
+1.04% | 998M |
- Stock Market
- Equities
- RIOT Stock
- News Riot Platforms, Inc.
- Venaxis, Inc. Begins Enrolling Patients into its Pivotal Clinical Study in the United States